Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

CRISPR Therapeutics AG - Common Shares (NQ:CRSP)

47.09 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 25, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about CRISPR Therapeutics AG - Common Shares

< Previous 1 2
...
29 30 31 32 33 34 35 36 Next >
News headline image
Why Are Crypto Mining Stocks RIOT, MARA, HUT Up Today? ↗
Crypto mining stocks are on the move Tuesday as investors react to Bitcoin (BTC) breaking past the $20,000 price point today! 
Via InvestorPlace
News headline image
Why Is Crispr Therapeutics (CRSP) Stock Up Today? ↗
Crispr Therapeutics (CRSP) stock is gaining on Tuesday after the FDA granted exagamglogene autotemcel (exa-cel) a rolling review. 
Via InvestorPlace
News headline image
Crispr Stock Jumps After Unveiling Timeline For FDA Submission Of First-Ever CRISPR Drug ↗
Crispr and Vertex nailed down the timeline for their blood diseases gene editor. 
Via Investor's Business Daily
News headline image
Why CRISPR Therapeutics Stock Is Rising Today ↗
CRISPR Therapeutics AG (NASDAQ: CRSP) shares are trading higher Tuesday after the company and Vertex Pharmaceuticals Inc (NASDAQ: VRTX) announced the U.S. 
Via Benzinga
News headline image
S&P 500 Giant Leads 5 Stocks Showing Strength In Bear Market ↗
Eli Lilly leads medical stocks setting up and showing relative strength. 
Via Investor's Business Daily
News headline image
If You Invested $1000 In This Stock 5 Years Ago, You Would Have $3,700 Today ↗
CRISPR Therapeutics (NASDAQ:CRSP) has outperformed the market over the past 5 years by 20.85% on an annualized basis producing an average annual return of 29.91%. Currently, CRISPR Therapeutics has a... 
Via Benzinga
News headline image
Where CRISPR Therapeutics Stands With Analysts ↗
CRISPR Therapeutics (NASDAQ:CRSP) has observed the following analyst ratings within the last quarter: 
Via Benzinga
News headline image
Intellia Therapeutics Looks To Repeat Its Landmark Success In CRISPR Gene Editing ↗
Intellia tested its CRISPR approach in cardiomyopathy and hereditary angioedema. 
Via Investor's Business Daily
News headline image
No One Told These 3 Stocks It’s a Down Week
At the individual stock level, there have been some interesting contrarian movers, especially in the electric vehicle (EV) space. 
Via MarketBeat
Topics Economy Electric Vehicles
News headline image
Something Unusual Is Happening Right Now With Biotech Stocks Like Catalyst, Vertex, Neurocrine And BioMarin ↗
The market is struggling, yet biotech stocks are acting like it's good times again. Here's why. 
Via Investor's Business Daily
News headline image
Neurocrine Leads 5 Stocks To Watch In Sickly Market ↗
Neurocrine Biosciences leads five medical stocks showing resilience. 
Via Investor's Business Daily
News headline image
Here's How Much $100 Invested In CRISPR Therapeutics 5 Years Ago Would Be Worth Today ↗
CRISPR Therapeutics (NASDAQ:CRSP) has outperformed the market over the past 5 years by 16.43% on an annualized basis producing an average annual return of 26.37%. Currently, CRISPR Therapeutics has a... 
Via Benzinga
News headline image
5 Top Stocks Cathie Wood Is Selling This Week ↗
Cathie Wood and her flagship ETF ARKK received $54.2 million of inflows earlier this month. Here's what she's selling. 
Via InvestorPlace
News headline image
5 Cathie Wood Stocks Signaling “The Bear Market Is Over” ↗
These top Cathie Wood stocks are signalling that the bear market is over. For savvy investors, that presents a chance to profit. 
Via InvestorPlace
News headline image
Why This Analyst Sees A 51% Return On This Cathie Wood-Favored Biotech Stock ↗
Biotech stocks have the potential for huge gains if a product or drug is deemed effective and safe, but investing in the shares of those companies can be volatile. 
Via Benzinga
News headline image
$1000 Invested In This Stock 5 Years Ago Would Be Worth $3,900 Today ↗
  CRISPR Therapeutics (NASDAQ:CRSP) has outperformed the market over the past 5 years by 19.58% on an annualized basis producing an average annual return of 31.2%. Currently, CRISPR Therapeutics has a... 
Via Benzinga
News headline image
Analysts See Softened Timelines For CRISPR Therapeutics' Sickle Cell Candidate In US ↗
 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For August 9, 2022 ↗
  
Via Benzinga
News headline image
Karuna Therapeutics To $276? Plus SVB Leerink Almost Doubles Price Target On This Stock ↗
Mizuho boosted the price target for Karuna Therapeutics, Inc. (NASDAQ: KRTX) from $190 to $276. Karuna Therapeutics shares fell 1.3% to $238.00 in pre-market trading. 
Via Benzinga
News headline image
NVIDIA To $240? Here Are 5 Other Price Target Changes For Tuesday ↗
Raymond James cut the price target on NVIDIA Corporation (NASDAQ: NVDA) from $250 to $240. Raymond James analyst Melissa Fairbanks maintained the stock with a Strong Buy. NVIDIA shares fell 2.8% to... 
Via Benzinga
News headline image
Small Cap Biotechs Perk Up On Dealmaking ↗
With M&A picking up we would think smaller deals make sense for large cap biopharma to expand pipelines and complement technology. 
Via Talk Markets
News headline image
MarketBeat: Week in Review 8/1 - 8/5
The hot jobs report is dispelling any notion that interest rates will level off. But the market moves on and here are some of the stocks and stories to follow. 
Via MarketBeat
Topics Economy Electric Vehicles
News headline image
Pfizer Is Reportedly In 'Advanced Talks' To Buy Global Blood Therapeutics For $5 Billion ↗
Shares of Pfizer's rumored takeover target have rocketed for two days running. 
Via Investor's Business Daily
News headline image
Cathie Wood Sheds $5M In CRISPR Therapeutics, Scoops Up These Biotech Stocks Instead ↗
Cathie Wood-led Ark Investment Management on Thursday sold 70,723 shares of gene editing company CRISPR Therapeutics AG (NASDAQ: CRSP), valued at over $5.58 million, via its flagship fund. 
Via Benzinga
News headline image
Why Are Gene Editing Stocks NTLA, ALNY, CRSP, BEAM Up Today? ↗
Gene editing stocks are a bright spot on the market today after Alnylam announced the success of one of its RNAi therapies, Patisiran. 
Via InvestorPlace
News headline image
Could CRISPR Therapeutics be a Moonshot Hiding in Plain Sight?
This article reviews the current state of affairs for CRISPR Therapeutics so you can decide if the gene editing company is worth a speculative investment 
Via MarketBeat
News headline image
Will a Recession Cause a Housing Crash in 2022? ↗
For stock investors looking for real estate exposure, the market dislocation also provides many once-a-decade deals. 
Via InvestorPlace
News headline image
7 Undervalued Biotech Stocks to Buy Before They Boom ↗
Despite recession fears, biological sciences will never go out of style, thus benefitting these undervalued biotech stocks to buy. 
Via InvestorPlace
News headline image
Small Cap Biotech Stocks Are Trending Well ↗
Despite a little weakness last week, small cap biotechs are trending well for traders. For investors entering the trade on July 5 all of our. focus stocks are up except ChemoCentryx. 
Via Talk Markets
News headline image
Crispr Therapeutics Stock Shows Rising Price Performance With Jump To 94 RS Rating ↗
Crispr Therapeutics sees its Relative Strength Rating enter the elite 90-plus level. 
Via Investor's Business Daily
< Previous 1 2
...
29 30 31 32 33 34 35 36 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.